北京大学器官移植研究所是2013年由北京大学器官移植中心（成立于2001年）更名成立的，是国内著名的器官移植研究机构。研究所由北京大学人民医院以及北京大学第一医院、北京大学第三医院、北京大学国际医院、北京大学肿瘤医院等北京大学附属的医疗机构和相关科室联合组成。研究所主体位于北京大学人民医院，由北京大学人民医院肝胆外科朱继业教授担任所长。

研究所主要开展肝移植、肾移植和角膜移植研究。目前已累计完成肝脏移植1000余例，肾移植近3000例，肝移植术后患者1年存活率达到90%以上，肝移植的数量和质量均在北方地区各家医疗单位中居于首位，在北京市肝移植准入评分排名中总分位列第一位。在北京率先开展活体肝移植手术，完成了活体扩大右半肝、右半肝及左半肝移植手术，开展了北京市第一例DCD肝移植手术和活体肝移植手术。研究所依托北京市肝硬化肝癌基础研究重点实验室一直致力于移植相关免疫耐受的基础研究，在移植免疫耐受的诱导及临床转化、干细胞定向分化、新型免疫抑制剂的作用机制研究、活体肝移植精准评估体系、DCD供体的评估和维护、肝癌肝移植预后评估体系的建立等科研方面取得了卓著的成绩。研究团队通过体外转化并扩增免疫抑制效力更强的双阴性调节T细胞，成熟建立了该细胞的体外转化、扩增、纯化的技术方案，并且通过研究其与B细胞的相互作用机制，发现其对B细胞的直接杀伤和抑制作用，并创新性的将其应用于慢性排斥反应动物模型中，得到了很好的实验结果，为进一步向临床转化治疗移植顽疾慢性排斥反应提供了一个新的潜在治疗途径。

机构负责人：朱继业

联系人：李照

邮箱：gandanwk@vip.sina.com

电话：010-88324175

地址：北京市西城区西直门南大街11号

The Peking University institute of organ transplant was established on Peking University organ transplantation center in 2013. It is a famous organ transplantation research institution in China. The institute includes medical institutions and the relevant departments of Peking University People's hospital, Peking University first hospital, Peking University third hospital, Peking University international hospital, Beijing cancer hospital and other affiliated hospitals of Peking University. The main body of the institute locates at Peking University People's hospital. The director of the institute is Jiye Zhu who is also the director of the department of hepatobiliary surgery, Peking University People's hospital. 

Liver transplantation, kidney transplantation and corneal transplantation can all be carried out in the institute. It has completed more than 1000 cases of liver transplantation, nearly 3000 cases of renal transplantation until now, of which the 1-year survival rate of patients after liver transplantation reaches more than 90%. Its quantity and quality of liver transplantations are both the highest among medical units in the northern region, whose total score ranked first in the Beijing liver transplant admission score. The institute took the lead in carrying out living donor liver transplantation in Beijing and completed the living expansion of the right hepatic, right hepatic and left hepatic transplantation. In addition, it also carried out the first case of DCD liver transplantation and living donor liver transplantation in Beijing. The institute has been committed to transplantation-related basic research of immune tolerance. Attached to Beijing Key Laboratory of Basic Research on Liver Cancer of Liver Cirrhosis, it achieved outstanding results in the induction and clinical transformation of transplantation immune tolerance, stem cell differentiation, the mechanism of novel immunosuppressive agents, accurate evaluation system of living donor liver transplantation, evaluation and maintenance of DCD donor, establishment of prognosis evaluation system of liver transplantation for liver cancer and other scientific research. Through in vitro transformation and amplification of double-negative regulatory T cell with more potent immunosuppression, the research team established a technical protocol for the transformation, amplification and purification of the cells in vitro. By studying the interaction of double-negative regulatory T cell with B cell, the institute found that the former could directly kill and inhibit B cells. The innovative application of this finding to animal models of chronic rejection has yielded good experimental results, providing a new potential therapeutic approach for further clinical treatment of chronic rejection of transplant stubbornness.